Abstract
Abstract immunomodulatory monoclonal antibodies used to strengthen the immune system against cancer have shown remarkable efficacy for patients with advanced melanoma and non-small cell lung cancer and are likely to significantly improve the survival of patients with several other malignancies. Events of clinical interest of a potential immunologic etiology (irECIs) may be defined as an adverse event of unknown etiology, associated with drug exposure and consistent with an immune phenomenon. Immune related adverse events (irAEs) may be predicted based on the nature of the compound and its mechanism of action. An irAE can occur shortly after the first dose or several months after the last dose of treatment. Such irAE represent a unique spectrum of side effects including dermatologic, gastrointestinal, hepatic, endocrine, and other less common inflammatory events. Even if most of them are mild and transient, they can be ocasionally severe or fatal. We will review the specific side effects of antibodies targeting the PD-1/PDL1, CTLA-4 and CSF1 receptors and discuss their physiopathology and potential impact on patient management. Citation Format: Antoine Italiano. Toxicities from immunomodulatory antibodies: An overview. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr CN03-01.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
